News coverage about Concert Pharmaceuticals (NASDAQ:CNCE) has trended somewhat positive recently, Accern Sentiment Analysis reports. Accern identifies positive and negative press coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Concert Pharmaceuticals earned a coverage optimism score of 0.23 on Accern’s scale. Accern also gave media coverage about the biotechnology company an impact score of 45.8666655129073 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
Several equities analysts have commented on CNCE shares. BidaskClub downgraded shares of Concert Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Friday, December 22nd. Mizuho reiterated a “hold” rating and set a $23.00 target price on shares of Concert Pharmaceuticals in a research note on Tuesday, February 13th. UBS set a $34.00 target price on shares of Concert Pharmaceuticals and gave the stock a “buy” rating in a research note on Tuesday, December 19th. Stifel Nicolaus reiterated a “buy” rating and set a $27.00 target price on shares of Concert Pharmaceuticals in a research note on Friday, January 12th. Finally, TheStreet upgraded shares of Concert Pharmaceuticals from a “d” rating to a “c+” rating in a research note on Wednesday, November 29th. Two research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $25.67.
Shares of Concert Pharmaceuticals (NASDAQ CNCE) traded up $0.36 on Friday, reaching $22.82. 248,667 shares of the company were exchanged, compared to its average volume of 312,738. Concert Pharmaceuticals has a 52-week low of $11.88 and a 52-week high of $30.71. The stock has a market capitalization of $530.18, a PE ratio of 5.71 and a beta of 1.07.
Concert Pharmaceuticals (NASDAQ:CNCE) last announced its quarterly earnings results on Thursday, March 1st. The biotechnology company reported ($0.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.08). Concert Pharmaceuticals had a net margin of 66.47% and a negative return on equity of 36.25%. The company had revenue of $0.01 million during the quarter, compared to analysts’ expectations of $8.11 million. analysts anticipate that Concert Pharmaceuticals will post -2.35 EPS for the current year.
In other news, insider Value Fund L. P. Biotechnology sold 1,282,856 shares of the company’s stock in a transaction dated Tuesday, December 19th. The shares were sold at an average price of $26.65, for a total value of $34,188,112.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Richard Aldrich sold 11,946 shares of the company’s stock in a transaction dated Thursday, February 1st. The shares were sold at an average price of $20.89, for a total transaction of $249,551.94. Following the completion of the sale, the director now directly owns 286,975 shares of the company’s stock, valued at $5,994,907.75. The disclosure for this sale can be found here. Insiders sold 1,419,092 shares of company stock valued at $36,876,675 over the last ninety days. Corporate insiders own 10.10% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Somewhat Favorable Press Coverage Somewhat Unlikely to Impact Concert Pharmaceuticals (CNCE) Stock Price” was originally reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this news story on another site, it was copied illegally and republished in violation of international trademark & copyright laws. The legal version of this news story can be read at https://ledgergazette.com/2018/03/18/somewhat-favorable-press-coverage-somewhat-unlikely-to-impact-concert-pharmaceuticals-cnce-stock-price.html.
About Concert Pharmaceuticals
Concert Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drugs. The Company operates through the development of pharmaceutical products on its own behalf or in collaboration with others. The Company’s deuterated chemical entity platform (DCE Platform), has potential across various therapeutic areas.
Receive News & Ratings for Concert Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Concert Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.